Clinical Scorecard: The Role of Gut Microbiota and Butyrate in Distinguishing Clostridioides difficile Colonization from Infection in Pediatric Patients
At a Glance
Category
Detail
Condition
Clostridioides difficile infection (CDI) versus asymptomatic colonization in children
Key Mechanisms
Differences in gut microbiota composition and fecal butyrate levels distinguish symptomatic CDI from asymptomatic colonization
Target Population
Pediatric patients aged 1 to 18 years, including those with cancer, inflammatory bowel disease, cystic fibrosis, and previously healthy children
Care Setting
Tertiary care children's hospital
Key Highlights
Symptomatic CDI is associated with increased abundance of Escherichia/Shigella, Haemophilus, and Gemella, and depletion of commensals such as Faecalibacterium, Blautia, and Bifidobacterium.
Fecal butyrate and butyrate-producing microbes are depleted in symptomatic CDI compared to asymptomatic colonization.
C. difficile toxin presence and bacterial burden do not reliably differentiate symptomatic infection from asymptomatic colonization in pediatric patients.
Guideline-Based Recommendations
Diagnosis
Use nucleic-acid amplification testing (NAAT) for detection of C. difficile gene tcdB.
Recognize that toxin detection alone does not distinguish symptomatic CDI from colonization in children.
Consider clinical symptoms (diarrhea ≥3 unformed stools in 24 hours with acute change) alongside laboratory results.
Management
Identify symptomatic CDI in children presenting with diarrhea and positive NAAT for targeted treatment.
Avoid unnecessary treatment in asymptomatic colonized children without diarrhea.
Monitoring & Follow-up
Monitor gut microbiota composition and butyrate levels as potential future biomarkers for CDI symptom development.
Observe clinical symptoms closely to differentiate CDI from other causes of diarrhea.
Risks
High rates of asymptomatic colonization in children with cancer, IBD, and cystic fibrosis may complicate diagnosis.
Misclassification may lead to overtreatment or undertreatment.
Patient & Prescribing Data
Pediatric patients with positive C. difficile NAAT, symptomatic and asymptomatic
Treatment decisions should be guided by symptom presence rather than toxin or bacterial burden alone due to overlap in colonization and infection states.
Clinical Best Practices
Incorporate clinical assessment of symptoms with laboratory testing to differentiate CDI from colonization.
Recognize the role of gut microbiota alterations and butyrate depletion in symptomatic CDI pathophysiology.
Use comprehensive microbiome and metabolite analysis to inform future diagnostic and therapeutic strategies.
by Maribeth R Nicholson, Siyuan Ma, Britton A Strickland, Mia Cecala, Lisa Zhang, Seth Reasoner, Emma R Guiberson, Matthew J Munneke, Meghan H Shilts, Eric P Skaar, Suman R Das
